Our Purpose
.png)
ELAM1 helps investors and finance professionals to gain a clear understanding of the scientific and clinical drivers behind healthcare innovation.
By combining scientific expertise with financial analysis, we offer the critical perspective needed to evaluate potential, mitigate uncertainty, and stay ahead in a fast-evolving sector.
Why ELAM 1?
Dual Expertise in Science & Finance
At ELAM1, our strength lies in the seamless integration of scientific depth and financial understanding. With a team experienced in both advanced biomedical research and financial analysis, we offer a unique perspective that bridges the gap between complex clinical data and strategic investment decision-making. This dual expertise allows us to translate scientific developments into financial insights, enabling our clients to assess opportunities with clarity.
.png)
Efficacy
At ELAM1, we pride ourselves on delivering clear, actionable insights that drive results. Our clients rely on us for timely, accurate, and in-depth analyses that cut through complexity and bring clarity to healthcare investment decisions.
.png)
Proprietary Methodologies
At ELAM1, our analyses are built on proprietary research methodologies that set us apart in the healthcare investment landscape. We elaborate our insights by integrating center-level real-world data, a strong network of key opinion leaders across therapeutic areas, and a deep understanding of both translational science and patient needs. This distinctive approach enables us to uncover dimensions of value and risk that standard models often overlook, providing our clients with a true competitive advantage.
.png)
Building a Partnership
We are committed to building long-term partnerships with our clients, grounded in a deep understanding of their strategic goals. Rather than offering one-off solutions, we position ourselves as a dedicated, ongoing partner—providing a follow up on our analysis and all along the investment's lifecycle.
.png)
Depth
ELAM1's expertise encompass a diverse range of investment of different size and at different stages of the company's lifecycle. It also span over 10+ therapeutic areas including oncology, cardiology and immunology. Our 15 years of experience has led to the enhancement of our market-shaping capabilities, allowing us to effectively navigate across emerging trends.
Dr. Louis-Emmanuel Chriqui,
MD-PhD
Dr. Louis-Emmanuel Chriqui is a practicing physician in the Department of Thoracic Surgery at Lausanne University Hospital, with a clinical focus on thoracic diseases and surgical oncology. He holds an MD-PhD in tumor biology and surgical oncology from the University of Lausanne.
As a clinician, Dr. Chriqui has been actively involved in the translational development of multiple preclinical studies and currently serves as a co-investigator in several clinical trials conducted at Lausanne University Hospital.
Prior to found ELAM1, Dr. Chriqui has worked for more than 10 years as an independent consultant and biotechnology analyst, advising various healthcare companies, venture capital firms and family offices in Switzerland and the United States.
E-mail: louis-emmanuel@elam1.com
Leadership
_edited.png)
Trusted By
.png)
.png)
